Pharmafile Logo

Research Partnership is on the rise

December 21, 2021 | Mark Jeffrey, Pharma, global healthcare 

Research Partnership ranks 12th in fastest growing UK market research agency league  tables

The UK’s best performing market research agencies were revealed this week with the publication of Research Live’s Industry Report for 2021, which includes the latest Market Research Society (MRS) League Tables. Based on available 2020 financial data that was compiled and analysed in November 2021, the MRS league tables identify and rank the best-performing research agencies and businesses according to their UK-based turnover and by their year-on-year growth.

In a very challenging year globally, Research Partnership bucked the trend by achieving an impressive 21% growth against an industry average of 0.8%. Less than half of the top 100 companies reported any growth.

Research Partnership ranked 23rd in the top individual agencies with a confirmed turnover of £40.297m and remains the UK’s largest individual healthcare consulting specialist.

The company ranked 7th in the top 20 fastest-growing businesses and 12th in the top 20 fastest-growing individual agencies.

Joint Founding Director Mark Jeffery commented, “Research Partnership has achieved considerable growth in a very turbulent climate. Fortunately, we were able to pivot quickly to remote working using online methodologies and we responded effectively to increased demand from our clients. Last year, we continued our recruitment drive and increased our headcount from 216 to 250 with appointments made across the US, EU and APAC offices. We also continued to grow both our market research and market access services, and we are winning business from both new and existing clients across the pharmaceutical, medtech and biotech sectors. According to our customer survey, satisfaction with insights and recommendations remained high and we are still delivering the quality service expected of us.”

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

AAD conference 2016

Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients

Video: Global Biosimilars Market

Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch

Case study: Understanding Patient Willingness to Pay in Emerging Markets

Our client wanted to identify the optimum selling price for their chronic disease treatment in emerging markets, based on patient’s willingness to pay for the product out of pocket.Find out...

From promise to practice: immuno-oncology in action Part 3 – Emerging Markets

Our latest white paper on immuno-oncology explores the challenges and opportunities in emerging markets, with a focus on Asia.

Infographic: HCV EU

Research findings from our Therapy HCV study shows that 28% of HCV patients in the EU are infected by sharing needles or drug equipment.Our latest market snapshot offers an introduction...

Taiwan: Exploring the Healthcare Opportunity in this Singular “Hybrid” Market

Published in eyeforpharma February 2016 by Rachel Howard

Gaining deeper insights within a hard to reach audience

Often a short research study isn’t sufficient to get the level of insights and understanding that you require, especially when working with a hard to reach target audience.It can also...

Living with RA Report

Living with Rheumatoid Arthritis 2016 is a new syndicated report which offers low-cost, high-value quantitative insight into patient attitudes and behaviour.

Heather Desmet appointed new Head of Living With

We are delighted to welcome Heather Desmet as Head of Living With at the company’s London headquarters.

Webinar Recording: The Art of Storytelling in Pharma Market Research

Effectively communicating research insights is a major focus for today’s market researcher, particularly in global healthcare. It’s not enough now just to present the research evidence. We must tell the...